Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Dec 9, 2013Seeking indication for prevention of chemotherapy-induced nausea and vomiting
Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the...
- Dec 5, 2013
Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual...
- Dec 4, 2013
Eisai Inc. announced today that five abstracts highlighting new study results will be presented during the 2013 San Antonio Breast Cancer...
- Dec 3, 2013Eisai Tackles Stigma Associated With Epilepsy Through Support Of Comic Book Addressing The Condition"Medikidz Explain Epilepsy" Aims to Help Children Better Understand the Disease
Eisai Inc., a leader in the epilepsy community, is proud to announce the availability of a first-of-its-kind comic book in the U.S. designed to...
- Nov 25, 2013
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has become a signatory to the Tuberculosis Drug...
- Nov 18, 2013Representatives Will Use Educational Tool for Up to 65,000 Physicians
Eisai and BusinessOne Technologies announced today that Eisai Inc. is using the Maestro Market Access Mobile™ application...
- Nov 13, 2013BELVIQ® (lorcaserin HCl) CIV Data Featured in Five Abstracts to be Presented at ObesityWeek(SM) 2013
Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that five abstracts highlighting new data analyses from...
- Nov 13, 2013Eisai to Convene Multidisciplinary Expert Panel in an Effort to Combat Growing Epidemic
A new survey conducted by Eisai Inc., in partnership with the Obesity Action Coalition (OAC) and The Obesity Society (TOS), reveals a...
- Nov 8, 2013
Eisai Inc. announced today that ACIPHEX® Sprinkle™ Delayed-Release Capsules 5mg and 10mg will be available to eligible patients by...
- Nov 7, 2013-- Collaboration to Focus on Global Commercialization and Development for Weight Management and Potential New Indications --
SAN DIEGO, CA and WOODCLIFF LAKE, NJ, November 7, 2013 – Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the BELVIQ® (lorcaserin HCl) marketing...
- Nov 1, 2013Award supports vital research to understand rare and severe form of epilepsy
The Child Neurology Foundation (CNF) and Eisai Inc. today announced that the first annual Michael SanInocencio Lennox-Gastaut Syndrome (LGS)...
- Oct 28, 2013FIRST SHIPMENT TO BENEFIT MORE THAN 6 MILLION PEOPLE IN 4 ENDEMIC COUNTRIES
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has begun the free supply of...
- Oct 15, 2013BELVIQ® Sales Force to Double in Size by December 2013
Eisai Inc. announced today that, as part of its long-term marketing strategy, the company will expand its sales force by adding more than 200...
- Oct 9, 2013Cornucopia Cancer Support Center™ Joins Forces with the Eisai Women’s Oncology Program - Magnolia™, CancerCare®, Cancer Support Community(SM) and Meals On Wheels Association of America™ to Help Ease the Stress of Those Living with Breast Cancer
Woodcliff Lake, NJ, October 7, 2013- Magnolia Meals at HomeTM, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now available in...
- Oct 9, 2013
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Children's Oncology Group (COG) has opened enrollment in a Phase 1 clinical study...
- Oct 1, 2013Eisai, CancerCare®, and Cancer Support Community(SM) Launch meal Trains(SM) sponsored by Magnolia™ During Breast Cancer Awareness Month; Campaign Aims to Drive 1,000 New meal Trains in October
Eisai Inc., along with collaborators CancerCare and Cancer Support Community, have announced meal TrainsSM sponsored by Magnolia™, which aim...
- Sep 16, 2013- Companies Initiate Multiple Co-discovery Programs for First-in-class Targets in Oncology -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology...
- Sep 12, 2013Eisai Launches BELVIQ® Patient Support Program Offering On-Line Tools to Enhance Weight Loss EffortsThe BELIEVE EVERYDAY SUPPORTSM Program Offers Customized Lifestyle Resources and Free Membership to Top Calorie Tracking App for Use by BELVIQ® (lorcaserin HCl) CIV Patients
Eisai Inc. today announced the availability of the BELIEVE EVERYDAY SUPPORTSM program to provide free, comprehensive support and savings for BELVIQ
- Aug 29, 2013
Eisai Inc. announced that the company has recently entered into a non-exclusive licensing agreement in the United States with a manufacturer of...
- Aug 19, 2013Epilepsy Drug Still Not Available to Patients 10 Months After FDA Approval
Eisai Inc. filed a petition today with the U.S. Court of Appeals for the District of Columbia asking the court to direct the Drug Enforcement...
- Aug 15, 2013
Eisai Inc. announced today the launch of a new website to provide employers with an educational resource for information about obesity...
- Aug 8, 2013
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound...
- Jul 8, 2013The Eisai Women’s Oncology Program - MagnoliaTM, CancerCare®, Cancer Support CommunitySM and Meals On Wheels Association of AmericaTM Are Working Together to Help Ease the Stress of Those Living with Breast Cancer in New Jersey
Woodcliff Lake, NJ, July 8, 2013- Magnolia Meals at Home™, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now available in Essex...
- Jul 3, 2013Earns V2.2 Gold Certification for New Construction
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has achieved LEED® certification for its new 60,000-square-foot pilot plant...
- Jun 20, 2013
Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that data from the BELVIQ® (lorcaserin HCl) Phase 3...